EUVIMEDEUVIMED entdecken
Open Access

PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors

Xianglai Xu, Jiahao Wang, Ying Wang, Yanjun Zhu, Jiajun Wang, Jianming Guo

Cellular Oncology · 2024

DOI: 10.1007/s13402-024-00977-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2024. Verfasst von Xianglai Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai, 200032, China. xl.xu@hotmail.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Biomarkers, Tumor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Zhongshan Clinical Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorImmune Checkpoint InhibitorsProtein Kinase InhibitorsDrug Resistance, NeoplasmHumansMalePrognosisFemaleMiddle AgedAgedProteasome Endopeptidase ComplexTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ICIPSMD2RCCT cell exhaustionTKI

Substanzen

Biomarkers, TumorImmune Checkpoint InhibitorsProtein Kinase InhibitorsProteasome Endopeptidase ComplexTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai, 200032, China. xl.xu@hotmail.com.
  • Department of Urology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, China. xl.xu@hotmail.com.
  • Department of Urology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Shanghai, 200032, China.
  • Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.

Förderung

  • Natural Science Foundation of Fujian Province
  • National Natural Science Foundation of China
  • Zhongshan Clinical Research Project
  • Shanghai Sailing Program
  • China Urological Oncology Research Fund

Zitieren

APA

Xu, X., Wang, J., Wang, Y., Zhu, Y., Wang, J., & Guo, J. (2024). PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors. Cellular Oncology. https://doi.org/10.1007/s13402-024-00977-z

Vancouver

Xu X, Wang J, Wang Y, Zhu Y, Wang J, Guo J. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors. Cellular Oncology. 2024. doi:10.1007/s13402-024-00977-z

BibTeX
@article{Xu2024,
  author = {Xu, Xianglai and Wang, Jiahao and Wang, Ying and Zhu, Yanjun and Wang, Jiajun and Guo, Jianming},
  title = {PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors},
  journal = {Cellular Oncology},
  year = {2024},
  doi = {10.1007/s13402-024-00977-z}
}
Kostenlos starten →